Targeting GALNT7 Disrupts the TAZ O-GalNAcylation Feedback Loop to Suppress Gallbladder Cancer Progression

Area of Science:

• Oncology
• Glycobiology
• Molecular Biology

Background:

• Gallbladder cancer (GBC) presents a significant challenge due to limited treatment options and poor prognosis.
• Identifying molecular drivers is essential for developing effective GBC therapies.

Purpose of the Study:

• To identify key molecular factors contributing to GBC progression.
• To elucidate the role of glycosyltransferases in GBC pathogenesis.
• To explore potential therapeutic targets for GBC.

Main Methods:

• Quantitative proteomics was employed to analyze GBC tissues.
• Protein-protein interaction studies were conducted.
• In vitro and in vivo GBC models were utilized.
• Structure-based drug screening was performed.

Main Results:

• GALNT7 was identified as the most upregulated glycosyltransferase in GBC, correlating with poor outcomes.
• GALNT7 promotes GBC by catalyzing TAZ O-GalNAcylation, stabilizing TAZ, and activating TEAD1-mediated transcription, forming a feedback loop.
• The PARP inhibitor Olaparib was identified as a GALNT7 antagonist, demonstrating anti-tumor efficacy in GBC models.

Conclusions:

• A novel glycosylation-dependent regulatory axis involving GALNT7 and TAZ drives GBC progression.
• GALNT7-TAZ signaling represents a promising therapeutic target for gallbladder cancer.
• Olaparib shows potential as a GBC therapeutic agent by inhibiting GALNT7 activity.